Hereditary spastic paraplegia (HSP) is a group of clinically and genetically heterogeneous neurological disorders characterized by pathophysiologic hallmark of length-dependent distal axonal degeneration of the corticospinal tracts. The prominent features of this pathological condition are progressive spasticity and weakness of the lower limbs. To date, 72 spastic gait disease-loci and 55 spastic paraplegia genes (SPGs) have been identified. All modes of inheritance (autosomal dominant, autosomal recessive, and X-linked) have been described. Recently, a late onset spastic gait disorder with maternal trait of inheritance has been reported, as well as mutations in genes not yet classified as spastic gait disease. Several cellular processes are involved in its pathogenesis, such as membrane and axonal transport, endoplasmic reticulum membrane modeling and shaping, mitochondrial function, DNA repair, autophagy, and abnormalities in lipid metabolism and myelination processes. Moreover, recent evidences have been found about the impairment of endosome membrane trafficking in vesicle formation and about the involvement of oxidative stress and mtDNA polymorphisms in the onset of the disease. Interactome networks have been postulated by bioinformatics and biological analyses of spastic paraplegia genes, which would contribute to the development of new therapeutic approaches.
Introduction
Hereditary spastic paraplegias (HSPs) constitute a heterogeneous group of neurodegenerative diseases characterized by genetic mutations that cause distal neuropathy of the longest corticospinal tract axons (Harding, 1993) ; ascending fibers (column of Goll and spinocerebellar tracts) are also often involved (reviewed in Blackstone, 2012; Deluca et al., 2004; reviewed in Orlacchio et al., 2006) . As a result of corticospinal dysfunction, progressive weakness and spasticity, extensor plantar responses, and hyperreflexia of deep tendon reflexes in lower limbs are common clinical features in pure forms. Iliopsoas, quadriceps femoris, and tibialis anterior are the muscles most affected by spasticity and weakness. Hypertonic bladder and lower limb sensory disturbances (generally mild, regarding vibration and joint position sense) may be present in pure forms too.
Other manifestations may occur in complicated forms, including above all cognitive impairment, cerebellar atrophy, polyneuropathy, thin corpus callosum (TCC), epilepsy, skeletal abnormalities, amyotrophy, and optic atrophy.
Age of onset is early childhood through 70 years. A recent systematic review from 12 studies performed since 1985 in European, Asian, and North African countries, estimated a global average prevalence of 1.8/10 5 for both ADHSP and ARHSP (reviewed in Ruano et al., 2014) . Pure forms are more prevalent in Northern Europe, Japan, and North America (Braschinsky et al., 2009; Ishiura et al., 2014) . Complicated forms are generally inherited as autosomal recessive traits (Coutinho et al., 1999) . In Mediterranean countries, these forms are more common due to the increased frequency of consanguinity.
To date, 72 different spastic gait disease-loci have been identified, and 55 spastic paraplegia genes (SPGs) have already been cloned. Other HSP causative genes are not in the SPG classification yet.
This review focuses on the clinical features and diagnostic clues for each genetic subtype of HSP, and on molecular pathogenesis including mitochondrial dysfunctions, the involvement of mitochondrial DNA polymorphisms/haplogroups and of oxidative stress in the disease. The recent discoveries of new causative genes also highlight the importance of ER function, morphogenesis, membrane shaping and endosome membrane trafficking, and vesicle formation in HSP pathophysiology.
Genetic classification of HSP
HSP can be transmitted in an autosomal dominant (AD), autosomal recessive (AR), X-linked (XL), or mitochondrial manner (reviewed in Finsterer et al., 2012; reviewed in Schüle and Schöls, 2011) . Nonetheless, sporadic HSP due to true de novo mutations, genealogical censure, non-penetrant AD mutations, or singleton in unrecognized AR kindred, is common. Fig. 1 shows the most frequent HSP causative genes. HSP forms and putative protein function of each HSP gene product are summarized in Table 1 . Inheritance and clinical features of each HSP form are described in Table 2 .
ADHSP
To date, 20 genetic SPG loci for ADHSP have been identified, but only 12 genes are known. There are at least eight identified ADHSP loci with an uncloned gene associated with the disease in both pure and complicated forms (Tables 1 and 2 ): SPG9 (Panza et al., 2008; Seri et al., 1999) , SPG19 (Valente et al., 2002) , SPG29 (Orlacchio et al., 2005a) , SPG36 (Schüle et al., 2009a) , SPG37 (Hanein et al., 2007) , SPG38 (Orlacchio et al., 2008b) , SPG40 (Subramony et al., 2009) , and SPG41 (Zhao et al., 2008) .
SPG3A
SPG3A/ATL1 mutations represent approximately 10% of ADHSP patients and are the most frequent cause of HSP with onset before age 10 years (Namekawa et al., 2006) .
ATL1 encodes atlastin-1, a member of the dynamin family of large guanosine triphosphatases, implicated in neurite outgrowth, intracellular membrane trafficking, but mainly in ER and Golgi morphogenesis, and in axon elongation during neuronal development (Byrnes and Sondermann, 2011; Rismanchi et al., 2008) .
Mutations are predominantly of missense type and whole genome and in-frame deletions have also been reported. Whole genome deletion of ATL1 was found in an SPG4 family, which did not co-segregate with the disease (Beetz et al., 2007) . A patient carrying the in-frame deletion of residue 436 (436delN) showed decreased atlastin-1 levels in lymphoblasts, but normal levels of mRNA, normal GTPase activity, and normal protein interactions. These features indicate that the pathogenic Fig. 1 . Timeline of gene discoveries and frequencies of the most frequent causative genes in familial (A) and sporadic (B) HSP. Epidemiological data of the HSP Italian network (total of 1707 affected subjects from all over the world). mechanism for SPG3A is not simply due to haploinsufficiency. A dominant-negative loss-of-function mechanism has been postulated .
The age of onset is around 4 years or, more rarely, later than that age. Very early onset cases develop severe spastic gait, contrary to late onset. Pure forms are the most common; additional symptoms include axonal polyneuropathy of small hand muscles (Silver syndrome) and TCC (Al-Maawali et al., 2011; Fusco et al., 2010; reviewed in Hedera, 2010; Orlacchio et al., 2011) .
SPG4
About 40% of ADHSP and about 20% of sporadic HSP are caused by mutations in SPG4/SPAST (Fig. 1) , encoding spastin . Spastin is a member of the ATPases associated with diverse cellular activities (AAA) family, with roles in microtubule dynamics and membrane trafficking. Four kinds of SPAST mRNA have been discovered, depending on the translation initiation codon used and alternative splicing of the exon 4 (reviewed in Salinas et al., 2007) . Spastin has two main structural domains: the microtubule interacting and transport (MIT) domain at the N-terminus, and the AAA catalytic domain in Cterminus. Over 300 mutations, including partial deletions, have been described; all pathogenic gene variants appear to affect the AAA domain, and act by a loss-of-function mechanism (haploinsufficiency) (Beetz et al., 2006) . Recently, intragenic copy-number variations have been found to cause the disease . The high concentration of Alu (highly homologous non low-copy repeats interspersed repetitive sequences) family members in the introns and flanking sequence of SPAST may predispose to intragenic rearrangements.
Most SPG4-patients show a pure phenotype, with average onset in the fourth decade of life, variably accompanied by column sensory deficits and, in about one third of cases, bladder disturbance (McDermott et al., 2006; Orlacchio et al., 2008a; Schulte et al., 2003) . SPG4 embraces a wide phenotypic variation, including the Silver syndrome (Orlacchio et al., 2008b) . The excess of males in published reports suggests that penetrance or severity may be sex-dependent (Orlacchio et al., 2005b; Proukakis et al., 2011) . Phenotypes complicated by cognitive impairment in executive functions (Ribaï et al., 2008) and by posterior fossa abnormalities (congenital arachnoid cysts) (Orlacchio et al., 2004a) have been reported.
SPG6
SPG6 is caused by mutations in NIPA1 (Kaneko et al., 2006; Munhoz et al., 2006; Rainier et al., 2003) . It comprises five exons encoding the non-imprinted in Prader-Willi/Angelman syndrome region protein 1.
Pure forms, with severe and rapidly progressive spasticity, are the majority. Polyneuropathy, cognitive impairment, and epilepsy are also reported (Du et al., 2011; Klebe et al., 2007; Svenstrup et al., 2011) .
SPG8
SPG8/KIAA0196 encodes strumpellin, a protein ubiquitously expressed and localized in cytoplasm and endoplasmic reticulum (ER). KIAA0196 mutations, reported in a few families with pure HSP (de Bot et al., 2013; Rocco et al., 2000) , lead to reduction of axonal outgrowth with a loss-of-function mechanism (Clemen et al., 2010) disrupting the endosome membrane trafficking (Freeman et al., 2013) .
SPG10
SPG10 is caused by mutations in KIF5A (Reid et al., 2002) . This gene codes for kinesin HC5A, a kinesin heavy chain. Most of KIF5A mutations are located in the highly conserved kinesin motor domain. Functional analyses showed an altered axonal transport, reducing the cargo flux and leading to deficient supply of the synapse (Ebbing et al., 2008) .
A recent study of ADHSP Western European families reported that SPG10 accounts for about 10% of complicated forms (Goizet et al., 2009c) . Moreover, a new phenotype present in SPG10 includes dysautonomia (Collongues et al., 2013) .
SPG12
SPG12/RTN2 encodes reticulon 2, a protein belonging to a large and diverse group of membrane-associated proteins found throughout the eukaryotic kingdom and named reticulons. These proteins regulate ER structure and functions and contain a uniquely conserved C-terminal domain (reticulon homology domain, RHD). RHD contains two putative transmembrane domains (TM1 and TM2), a loop region and a short Nterminus (reviewed in Chiurchiù et al., 2014) . Reticulon 2 interacts with spastin. Mutations can be frameshift, missense, and whole gene deletion, presumably leading to haploinsufficiency. SPG12 is a pure and rapid progressive HSP (Montenegro et al., 2012; Orlacchio et al., 2002) .
SPG13
SPG13/HSPD1 encodes a mitochondrial protein, the heat shock protein 60 chaperone (Hsp60), which assists the folding of several proteins localized in mitochondria.
SPG13 occurs between 1 and 60 years of age; in addition to pure form with loss of vibratory sensation, it was associated with dystonia, which improves upon deep brain stimulation (Gilbert et al., 2009; Hansen et al., 2002) .
SPG17
SPG17/BSCL2 encodes seipin, an ER integral membrane protein whose function is unknown. The two identified missense mutations affect its glycosylation and result in an accumulation of unfolded protein in the ER. This probably triggers the unfolded protein response (UPR) and cell death, suggesting that these diseases are tightly associated with ER stress.
SPG17 causes Silver syndrome that includes amyotrophy of small hand muscles. Nerve conduction studies often disclose severe reduction of compound muscle action potentials (CMAPs) (Windpassinger et al., 2004) .
SPG17 is allelic to congenital generalized lipodystrophy type 2 (also termed Berardinelli-Seip congenital lipodystrophy), distal hereditary motor neuropathy type V (dHMN V), and Charcot-Marie-Tooth disease 2 (CMT2) (reviewed in Ito and Suzuki, 2009 ).
SPG31
SPG31/REEP1 encodes the receptor expression-enhancing protein 1, a mitochondrial protein that might be involved in chaperon-like activities. Missense, splice site, nonsense, insertion and deletion mutations are known. Loss of function and haploinsufficiency are the major mechanisms of action in SPG31 (Battini et al., 2011) . Functional studies showed abnormal mitochondrial network organization in fibroblasts of one patient, in addition to defective mitochondrial energy production (Goizet et al., 2011) .
Only a few patients show a complicated HSP form (Beetz et al., 2008; Goizet et al., 2011) .
SPG33
SPG33 was reported in a single German family with complicated HSP and mutation (p.G191V) in ZFYVE27 (Mannan et al., 2006) . It encodes a specific spastin-binding protein, protrudin, a member of the FYVE-finger family of proteins. The mutated protein shows an aberrant intracellular pattern in its tubular structure impairing its interaction with spastin and affecting neuronal intracellular trafficking in the corticospinal tract.
The disease-related role remains unsettled (Martignoni et al., 2008) .
SPG42
SPG42/SLC33A1 encodes the acetyl-CoA transporter, a multiple transmembrane protein in the ER. It carries acetyl-CoA into the lumen of Golgi apparatus, where it is transferred to the sialyl residues of gangliosides and glycoproteins. This modification may play a critical role in the outgrowth BMP = bone morphogenic protein; del = deletion; dupl = duplication; ER = endoplasmic reticulum; ERAD = ER-associated degradation; indel = insertion/mutation; ins = insertion; Mit = mitochondrial; PM = point mutation; PPF = protein putative function; TOM = type of mutation; ss = splice site mutation; Ua = unassigned SPGs. A single, large Chinese family, harboring the missense p. S113R, has been reported with a possible loss of function (Lin et al., 2008) .
SPG72
In affected members of a large French family with ADHSP, it has been identified a heterozygous missense mutation in the REEP2 gene (Esteves et al., 2014) (Tables 1 and 2 ). ARHSP Forty-eight SPG loci and 41 genes responsible for ARHSP have been identified so far. Several other ARHSP loci, namely SPG14 (Vazza et al., 2000) , SPG23 (Blumen et al., 2003) , SPG24 (Hodgkinson et al., 2002) , SPG25 (Zortea et al., 2002) , SPG27 (Meijer et al., 2004; Ribaï et al., 2006) , SPG32 (Stevanin et al., 2007a) , and SPG45 (Dursun et al., 2009) , have been identified but pathological genes are yet unknown (Tables 1  and 2 ).
SPG5A
SPG5A/CYB7B1 encodes cytochrome P450 oxysterol 7-hydroxylase, implicated in biosynthesis, storage and catabolism of brain cholesterol metabolites. The gene product of CYP7B1 also participates in the "acidic" pathway of bile acid synthesis . The role of 27-hydroxy-cholesterol blood accumulation in SPG5A-patients, its role as pathogenetic player and its utility in clinical practice is still debated (Schüle et al., 2010) .
More than 20 different mutations were reported (Goizet et al., 2009a; Schüle et al., 2009b; Tsaousidou et al., 2008) . Pure form is the most common; periventricular and subcortical white matter lesions (WMLs) are observed in many patients (Biancheri et al., 2009) . Electrophysiological investigations revealed pathologic motor evoked potentials (MEPs), sensory evoked potentials (SEPs), visual evoked potentials (VEPs), and auditory evoked potentials (AEPs), in contrast with normal nerve conduction study and EMG (Manganelli et al., 2011) .
SPG7
SPG7/PGN encodes paraplegin, one of the proteins forming the m-AAA protease complex located in the mitochondrial membrane. This protein is constituted by two peptide regions, a metallo-peptidase domain and an ATPase domain (reviewed in Langer, 2000) . PGN variants identified to date are almost all nonsense loss-of-function mutations or missense mutations in the metallo-peptidase domain (Casari et al., 1998) ; however, some mutations cause an amino acid substitution mapping in the AAA-domain. Paraplegin is involved in the removal of damaged or misfolded proteins, the proteolytic activation of essential mitochondrial proteins and ribosome maturation; ultrastructural studies showed abnormal shaping of mitochondria (Nolden et al., 2005) .
Patients may show cerebellar signs or cerebellar atrophy (Brugman et al., 2008; Elleuch et al., 2006) that, in addition to optic neuropathy (or abnormalities on optical coherence tomography), are key features for the diagnosis of SPG7 (Klebe et al., 2012b) .
SPG11
SPG11/KIAA1840 mutations are the most common cause of ARHSP (Stevanin et al., 2007b . Genetic analyses of KIAA1840 revealed several types of mutations leading to protein loss of function. Recent identification of repeated Alu elements should be linked to SPG11 locus instability, making this genomic region prone to large gene rearrangements (Conceição Pereira et al., 2012) . KIAA1840, encoding spatacsin, is expressed ubiquitously in the nervous system, but most prominently in the cerebellum, cerebral cortex, hippocampus and pineal gland. The specific role of peptide remains unknown, though it seems to be essential to the survival of neurons (Crimella et al., 2009; Southgate et al., 2010) .
KIAA1840 mutations have been identified as a genetic cause of juvenile amyotrophic lateral sclerosis type 5 (ALS5) in 40% of patients (Orlacchio et al., 2010) and Kjellin syndrome (Orlén et al., 2009 ) characterized by central retinal degeneration, mental retardation and amyotrophy in addition to ARHSP-TCC.
On average, patients become wheelchair-bound 16 years after disease onset. Cognitive impairment and TCC are reliable phenotype predictors of SPG11; other common features are axonal polyneuropathy and cerebellar signs (Del Bo et al., 2007; Pippucci et al., 2009; Stevanin et al., 2006) . Hehr et al. (2007) hypothesized that phenotype results from the combined degeneration of central and peripheral axons and neuronal loss within cortical and thalamic regions and in the spinal cord.
SPG15
Patients carrying mutations in SPG15/ZFYVE26, encoding spastizin, show similar symptoms to those observed in SPG11 (Table 2) . Mutations lead to loss of protein or mutated forms of protein with defective autophagy (Vantaggiato et al., 2013) .
Originally mapped in families with Kjellin syndrome (Hanein et al., 2008; Kjellin, 1959) , SPG15 is the second most common cause of HSP-TCC (Goizet et al., 2009b) . Being relatively rarer than SPG11, genetic test is recommended in SPG11 negative patients only. ACC = agenesis corpus callosum; AO = adult onset; AD = autosomal dominant; AR = autosomal recessive; C = complicated; CI = cognitive impairment; CS = cerebellar signs; EO = early onset (infancy); IGE = idiopathic generalized epilepsy; MI = mode of inheritance; NOF = number of families; OA = optic atrophy; P = pure; PNP = polyneuropathy; TCC = thin corpus callosum; TO = teenage onset; VO = variable onset (infancy, teenage, or adult); WMLs = white matter lesions.
SPG18
ERLIN2 in the SPG18 locus encodes SPFH2 protein that contains a characteristic SPFH (stomatin-prohibitin-flotillin-HflC/K) domain. This peptidic region makes the protein capable of assembling into an oligomeric structure anchored to the cellular membrane. SPFH2 has been shown to regulate the ER-associated degradation (ERAD) pathway by interacting with endogenous proteins and resulting in their polyubiquitination and proteasome degradation (Pearce et al., 2007) .
Three loss-of-function mutations in ERLIN2 have been reported in families from Saudi Arabia (Alazami et al., 2011; Wakil et al., 2013; Yildirim et al., 2011) . Patients carrying a nullimorphic ERLIN2 mutation showed additional features of mental retardation, late epilepsy and hip dislocation (Alazami et al., 2011) .
SPG20
Troyer syndrome is a complicated ARHSP that occurs with high frequency in Amish people and it was also reported in two Omani families: a frameshift mutation due to a single base deletion producing a truncated SPG20/spartin protein and two null mutations were reported in SPG20 (Bakowska et al., 2008; Manzini et al., 2010; Patel et al., 2002) . The encoded protein, spartin, has been considered as a multifunctional protein, playing a role in protein folding and turnover, both in mitochondria and ER. It seems to have a crucial function in the ubiquitination and degradation of lipid droplet-associated proteins (Milewska et al., 2009) . Spartin contains several distinct domains including an Nterminal MIT region, which is responsible for its interaction with microtubule and trafficking molecules (Ciccarelli et al., 2003) .
Troyer syndrome is characterized by mental retardation, distal muscle wasting, dysarthria, and quadriparesis. Cerebellar signs, choreoathetosis, euphoria, crying, and WMLs on brain MRI may also be observed .
SPG21
Mast syndrome, initially described by Cross and McKusick (1967) , is a complicated form of ARHSP associated with dementia and other CNS abnormalities, that is present at high frequency among the Old Order Amish. It is caused by SPG21/ACP33 mutations. The single base-pair insertion reported in an Amish pedigree results in the premature termination of the encoded product maspardin. This protein has been shown to localize in vesicle of the endosomal/trans-Golgi network, highlighting a possible role of this protein in cellular transport and sorting, and its role in neuronal cells has been confirmed in SPG21 −/− knockout mice, which also showed alterations in axon branching (Soderblom et al., 2010) . SPG21-patients, in addition to slowly progressive pure phenotype that develops in early adulthood, may show cerebellar and extrapyramidal signs in the advanced disease. Most of patients have TCC and WMLs on MRI (Simpson et al., 2003) . Recently, a missense mutation (p.A108P) in APC33 was identified in a Japanese family .
SPG26
SPG26/B4GALNT1 encodes β-1,4-N-acetyl-galactosaminyl transferase 1, involved in ganglioside biosynthesis. Gangliosides belong to the family of glycosphingolipids, which are components of the synaptic plasma involved in synaptic plasticity, signal transduction, and endocytosis. B4GALNT1 catalyzes the transfer of N-acetyl-galactosamine into GM3, GD3, and globotriaosylceramide by a β-1,4 linkage. The reverse reaction is performed by β-hexosaminidase and its cofactor (GM2 activator). Molecular defects in the degradation of glycosphingolipids lead to lysosomal storage diseases.
Truncating, missense mutations, and deletions of B4GALNT1 cause complicated early onset ARHSP . It is worthy of note that SPG26 is the second disorder of ganglioside biosynthesis after SPG46 (Martin et al., 2013) . These findings confirm the increasing interest of lipid metabolism in HSP.
Patients carrying the B4GALNT1 mutation had an early onset (2 to 19 years) spastic paraplegia with intellectual impairment. About a third of such patients also had mild upper limb involvement. Other features were more variable .
SPG28
Truncating mutations in SPG28/DDHD1, encoding PAPLA1 (phosphatidic-acid-preferring phospholipase A1), are reported in pure and complicated HSP.
PAPLA1 is involved in the maintenance of the ER and Golgi structures. DDHD1 mutations also cause mitochondrial dysfunction, including reduced respiration and ATP production that might result from the accumulation of PA in mitochondria. Therefore, DDHD1 might also be involved in similar functions in the maintenance of organelle membranes and intracellular trafficking (Higgs et al., 1998; Nakajima et al., 2002; Tani et al., 1999) .
The discovery of DDHD1 mutations in three additional SPG28-affected subjects extended the clinical spectrum of this disease, compared to the pure phenotype originally described in a single Moroccan family (Bouslam et al., 2005; Tesson et al., 2012) .
SPG30
SPG30/KIF1A encodes the kinesin 3 protein. The protein belongs to the kinesin-3 family that is involved in intracellular anterograde transport of dense core vesicles (DCVs), containing neuropeptide cargos, along microtubules to the pre-and post-synaptical cellular regions: gene deletion determines a reduction of DCVs at synapses, followed by an accumulation of such vesicles in the cell body and neuronal death (Lo et al., 2011) .
Missense mutations have been reported (Erlich et al., 2011; Klebe et al., 2012a) , causing early onset and slow progressive HSP. Nonsense mutations in the same gene cause hereditary sensory neuropathy type IIC (HSN2C) (Rivière et al., 2011) .
SPG35
FA2H enzyme catalyzes the synthesis of sphingolipids containing 2-hydroxy fatty acids; these biochemical compounds participate in several biological processes. In particular, SPG35/FA2H null mice suggested that the protein is necessary in long-term maintenance of myelin (Zöller et al., 2008) . SPG35 is generally characterized by childhood onset of gait difficulties, dysarthria, cognitive impairment, and leukodystrophy on MRI (Dick et al., 2010) . FA2H mutations are involved in other two neurodegenerative diseases: leukodystrophy with spastic paraparesis and dystonia (Edvardson et al., 2008) and neurodegeneration with brain iron accumulation (NBIA). Kruer et al. (2010) referred to this phenotypic spectrum of disorders as fatty acid hydroxylase associated neurodegeneration (FAHN).
SPG39
The gene at the SPG39 locus has been identified in a novel HSP, designated NTE-related motor neuron disease (NTE-MND) (Rainier et al., 2008) : it is the neuropathy target esterase gene (NTE), encoding PNPLA6. The protein plays a role in axonopathy produced by organophosphorus compounds; moreover, knockdown experiments show that it is also implicated in survival of developing embryos (Moser et al., 2004) .
Reported point mutations, disrupting the catalytic domain, decrease hydrolysis activities and alter the ability to be reactivated by nucleophiles (Hein et al., 2010 ). An insertion mutation, causing frameshift and protein truncation, is also reported in compound heterozygosity (Synofzik et al., 2014) .
The affected phenotype in each family conformed both to organophosphorus compound-induced delayed neuropathy (OPIDN) and to Troyer-like syndrome. In childhood, patients exhibit features of the pure form later associated with wasting of distal leg and intrinsic hand muscles. Electrophysiological studies were consistent with a motor axonopathy affecting upper and lower limbs. Single SPG39-patient showed atrophy of the spinal cord, particularly in the thoracic region on MRI (Rainier et al., 2008) .
SPG43
SPG43, previously described in two Malian sisters (Meilleur et al., 2010) , is caused by missense mutation or nucleotides deletion in C19orf12 (Landouré et al., 2013) . Mutations in the same gene are also reported in a series of patients with NBIA (Hartig et al., 2011) .
In addition to Silver syndrome, patients may have bilateral optic atrophy or axonal sensory motor polyneuropathy and MRI evidenced iron deposits in the globus pallidus of Brazilian patients, linking with SPG43 and NBIA (Landouré et al., 2013) .
SPG44
SPG44 is caused by a homozygous point mutation in GJC2, encoding connexin-47 (Orthmann-Murphy et al., 2009). Recessive mutations in this gene also cause Pelizaeus-Merzbacher-like disease (PMLD), which is characterized by severe CNS demyelination (Orthmann-Murphy et al., 2007) . Connexin-47 is constituted by four transmembrane, two extracellular, and three cytoplasmic domains. This protein belongs to the connexin family and it forms gap junctions (intercellular channels), allowing direct cell-to-cell diffusion of ions and small molecules.
SPG44-related patients (three members of a large Italian family) had pes cavus and a late onset slowly progressive paraplegia. Brain MRI showed a hypomyelinating leukodystrophy and TCC in all three patients. Other features in individual patients include dysarthria, loss of finger dexterity, dysmetria, intention tremor, scoliosis, upper limb involvement, and cognitive impairment (Orthmann-Murphy et al., 2009).
SPG46
Four different mutations in GBA2 (glucosidase beta bile acid 2), three truncating variants, and one missense variant, were identified in four unrelated SPG46 families (Martin et al., 2013) . This is a complicated form with slowly progressive spastic paraplegia and cerebellar signs. Some patients show cerebral and cerebellar atrophy and TCC on brain MRI (Boukhris et al., , 2010 Martin et al., 2013) . Homozygous mutations in GBA2 were also found in patients with autosomal recessive cerebellar ataxia and spasticity (Hammer et al., 2013) .
GBA2 encodes a microsomal non-lysosomal glucosylceramidase, localized in the endoplasmic reticulum and at the cell surface, which catalyzes the conversion of glucosylceramide to free glucose and ceramide and the hydrolysis of bile acid 3-O-glucosides. Ceramides formed by this enzyme are rapidly converted into sphingomyelin (Yildiz et al., 2006) . The missense variant was also found at the homozygous state in a single patient, in whom no residual glucocerebrosidase activity of GBA2 was proven in blood cells, opening the way to a possible measurement of this enzyme activity in clinical practice (Martin et al., 2013) .
SPG47, SPG50-SPG52
These neurodegenerative disorders are characterized by neonatal hypotonia of all limbs that progresses to spasticity and severe mental retardation with poor or absent speech development (Abou Jamra et al., 2011).
Mutations in genes encoding heterotetrameric adaptor protein 4 complex (AP4) subunits were identified: a frameshift mutation (Abou Jamra et al., 2011) and a truncating mutation (Bauer et al., 2012) in SPG47/AP4B1, a splice mutation in SPG51/AP4E1 (Abou Jamra et al., 2011) and a nonsense mutation in SPG52/AP4S1 (Abou Jamra et al., 2011). Two mutations affecting SPG50/AP4M1 and AP4E1 have recently been found to cause cerebral palsy associated with severe intellectual disability (Verkerk et al., 2009 ).
Moreno- De-Luca et al. (2011) proposed the designation of 'AP4 deficiency syndrome' to refer to disorders caused by disruption of any of the four AP4 subunits.
SPG48
An insertion/deletion has been found in SPG48/KIAA0415 in two HSP siblings; KIAA0415 encodes a putative helicase (AP5Z1), with both nuclear and cytoplasmic localization, involved in DNA double-strand break repair processes and known to be a spatacsin and spastizin interactor. In particular, spatacsin is phosphorylated upon DNA damage by protein kinases ATM (ataxia telangiectasia mutated) or ATR (ATM and Rad3-related) (Słabicki et al., 2010) . A recent study showed that the protein is a member of the adaptor protein 5 complex (AP5) that is implicated in vesicle formation and sorting (as AP4) (Hirst et al., 2011) .
The two siblings, in the single French family reported, presented spastic paraplegia associated with urinary incontinence. One had spinal hyperintensities on MRI in the cervical spine. The unaffected parents were from two neighboring villages (Słabicki et al., 2010) .
SPG49
Oz-Levi et al. (2012) identified a homozygous truncating mutation in SPG49/TECPR2 (tectonin beta-propeller repeat containing 2) in a form of complicated HSP. This HSP is characterized by onset of spastic paraplegia in the first decade, delayed psychomotor development, mental retardation, dysmorphic features (such as short stature, mild brachycephalic microcephaly, round face, low anterior hairline, dental crowding, short broad neck, a chubby appearance), dysarthria, dysmetria, TCC on brain imaging and episodes of central apnea.
SPG53
A homozygous mutation in SPG53/VPS37A (vacuolar protein sorting 37A), a member of the endosomal sorting complex required for transport (ESCRT) system, has been described in a complicated HSP (Zivony-Elboum et al., 2012) . The system plays a central role in intracellular trafficking, maturation of multivesicular bodies, and sorting of ubiquitinated membrane proteins into internal luminal vesicles (Raiborg and Stenmark, 2009) .
Disease progresses from onset in infancy of delayed motor development to upper and lower limb spasticity. Affected individuals also show mild to moderate cognitive and speech delay.
SPG54
Biallelic or homozygous frameshift and missense mutations of SPG54/DDHD2 were identified in a complicated early onset HSP (Schuurs-Hoeijmakers et al., 2012) .
The DDHD2 protein belongs to the mammalian intracellular phospholipase A 1 , implicated in organelle biogenesis and membrane trafficking. DDHD2 preferentially hydrolyzes phosphatidic acid but also exhibits activity toward phosphatidylethanolamine. RNA-interference experiments in cellular systems indicated a role of DDHD2 in transport from the Golgi to the plasma membrane. In view of this, it was hypothesized that DDHD2 facilitates membrane and vesicle fusion by the modification of membranes through phospholipid hydrolysis (Inoue et al., 2012; Morikawa et al., 2009; Nakajima et al., 2002; Sato et al., 2010; Tani et al., 1999) .
Phenotype among all six families was relatively homogeneous (Table 2) with mental retardation and early onset of progressive spasticity before the age of 2 years. In line with the function in lipid metabolism, an abnormal lipid peak indicating accumulation of lipids was detected with cerebral magnetic resonance spectroscopy (MRS) with the highest intensity around the basal ganglia and thalamus. This can be an applicable diagnostic biomarker to distinguish the SPG54 phenotype from other complicated HSP (Schuurs-Hoeijmakers et al., 2012).
SPG55
A nonsense mutation in SPG55/C12orf65 was identified in two patients with HSP complicated by optic atrophy and polyneuropathy in a Japanese family (Shimazaki et al., 2012) .
The C12ORF65 protein belongs to the mitochondrial class I peptide release factors. Its function is still not clear. It might play a role in recycling abortive peptidyl-tRNAs that were prematurely released from ribosomes during polypeptide elongation (Antonicka et al., 2010; Richter et al., 2010) . This mutation causes marked reduction of mitochondrial protein synthesis, followed by functional and structural defects in respiratory complexes I and IV. A study in cultured neurons showed that complex I deficiency could increase mitochondrial reactive oxygen species leading to neuronal death (Abramov and Duchen, 2010) .
SPG56
CYP2U1 is a cytochrome P450 protein implicated in ω-and ω − 1 fatty-acid (C16-C22) hydroxylation. CYP2U1 is able to catalyze the hydroxylation of arachidonic acid and related long-chain fatty acids such as eicosapentaenoic and docosahexaenoic acids. Two known metabolites, 19-and 20-hydroxyeicosatetraenoic acids, are local mediators of signal transduction (Carroll and McGiff, 2000; Chuang et al., 2004) .
Missense and deletion mutations in SPG56/CYP2U1 are reported in five unrelated families with ARHSP (Tesson et al., 2012) . Affected individuals developed spastic paraplegia with a range from birth to 8 years. Symptom severity varied widely: complicated phenotype includes upper limbs involvement, dystonic posturing of the upper limbs, mental retardation, subclinical axonal polyneuropathy, WMLs on brain MRI, calcifications in the globus pallidus and TCC (Citterio et al., 2014) .
SPG57
In two siblings with early onset spastic paraplegia, optic atrophy, and polyneuropathy, a genetic analysis revealed a homozygous variant, p.R106C, in Trk-fused (TFG) as the only plausible mutation . Intriguingly, a heterozygous mutation, p.P285L, was demonstrated in a distinct phenotype called hereditary motor and sensory neuropathy with proximal dominant involvement (HMSN-P) .
Native TFG functions affect vesicle biogenesis on the ER, the formation of a matrix between ER exit sites and the ER-Golgi intermediate compartment, a sorting hub for secretory cargoes in metazoan cells (Witte et al., 2011) . Mutant protein lacks its ability to self-assemble into an oligomeric complex, which is a critical phase for normal TFG function. In cell lines, TFG inhibition slows protein secretion from the ER and alters ER morphology, disrupting organization of peripheral ER tubules and causing collapse of the ER network onto the underlying microtubule cytoskeleton .
SPG58-SPG72
Very recently, 15 candidate genes for ARHSP were reported and the assigned locus for HSP increased up to SPG72 (Esteves et al., 2014; Novarino et al., 2014) (Fig. 2, Tables 1 and 2 ). Based on the putative biological function, most of these genes can be stratified into the functional modules described below.
XLHSP
To date, five X-linked SPG loci, named SPG1, SPG2, SPG16, SPG22, and SPG34, and three genes (L1CAM, PLP1, and SLC16A2) have been identified. Gene identity at the SPG16 (Steinmuller et al., 1997) and SPG34 (Macedo-Souza et al., 2008) loci are unknown (details in Tables 1 and 2 ).
SPG1
X-linked hydrocephalus, MASA (mental retardation, aphasia, shuffling gait, and adducted thumbs) syndrome, X-linked complicated SPG1 and X-linked partial agenesis of the corpus callosum are the four diseases usually referred to L1 syndrome, caused by mutations in SPG1/L1CAM (Jouet et al., 1994) . Its product (NCAM) is a transmembrane glycoprotein mainly expressed in neurons and Schwann cells.
SPG2
SPG2 is caused by mutations in PLP1 (proteolipid protein 1), encoding myelin proteolipid protein (MPLP), the major myelin protein responsible for stabilization and maintenance of the myelin sheath. PLP1 variants also lead to Pelizaeus-Merzbacher disease, a hypomyelination disorder having onset in infancy and death in young adulthood (Saugier-Veber et al., 1994) . Several mutations in PLP1 have been identified ranging from entire gene duplications, deletions, and intragenic sequence variants (Cailloux et al., 2000) .
Only males are affected, exhibiting slowly progressive paraplegia; some patients have nystagmus, ataxia, cerebral or spinal WMLs, polyneuropathy, and, in a single case, dementia (Suzuki et al., 2011) .
SPG22
This HSP is caused by mutations in SPG22/SLC16A2 encoding monocarboxylate transporter 8 (MCT8) (Schwartz et al., 2005) . The protein is essential in triiodothyronine transport into neurons, and contributes to axon pathfinding (reviewed in Blackstone et al., 2011) ; its abnormal function is reflected in elevated free triiodothyronine and lowered free thyroxine levels in the blood (Friesema et al., 2003) .
Clinical manifestations in complex form (Allan-Herndon-Dudley syndrome) include severe mental retardation, dysarthria, athetoid movements, muscle hypoplasia, and spastic paraplegia (Boccone et al., 2010; Schwartz et al., 2005) .
Unassigned SPGs

GAD1 gene
A homozygous nonsense mutation in glutamic acid decarboxylase 1(GAD1) leading to a protein truncation has been identified in patients from consanguineous Pakistan families; affected subjects had cerebral palsy and mental retardation (Lynex et al., 2004) .
GAD1 encodes for the 67 kDa isoform of L-glutamate decarboxylase (GAD 67 ), which is involved in conversion of the excitatory neurotransmitter glutamate to the inhibitory neurotransmitter GABA. The glutamatergic excitotoxicity may play a role in this context too.
Cct5 gene
Cct5 encodes the epsilon subunit of the cytosolic chaperonincontaining t-complex peptide-1 (CCT): a homozygous missense mutation p.H147R was identified in this gene in four patients from a consanguineous Moroccan family, displaying mutilating sensory neuropathy associated with spastic paraplegia (Bouhouche et al., 2006) . Molecular chaperones play an important role in the folding of many proteins and the CCT complex is a member of the two major chaperone systems that promote folding and assembly of a wider range of cytosolic substrates (actin and tubulin in particular).
OPA3 gene
Mutations in this gene cause 3-methylglutaconic aciduria type III (Costeff optic atrophy syndrome) (Anikster et al., 2001 ) and autosomal dominant optic atrophy and cataract (Reynier et al., 2004) . In a recent study, two cousins from consanguineous parents showed, in addition to optic atrophy, motor symptoms from the age of 3 to 4 years including chorea, cerebellar ataxia, dystonia, and pyramidal tract signs of lower limbs. Exome sequencing revealed 2 homozygous variants (c.32 TNA [p.L11Q] in OPA3 and c.941 CNG [p.A314G] in TSHZ3) that segregated with the disease. Only the OPA3 variant was absent in the control subjects and predicted to be damaging (Arif et al., 2013) .
The function of the OPA3 protein is important for mitochondrial dynamics and respiratory chain complex protein stability (Grau et al., 2013) .
BICD2, MAG, and LYST genes
These three genes were lately found mutated in ARHSP patients (Novarino et al., 2014; Shimazaki et al., 2014) (Fig. 2 , Tables 1 and  2 ).
HSP with maternal inheritance
A late onset HSP due to m.9176 TNC mtDNA mutation in MT-ATP6 in five members of a large family is the first and sole maternally-inherited form of HSP described to date (Verny et al., 2011) . Variable clinical presentation is the hallmark of mtDNA mutations: for example, like the more common m.8993 TNG, the m.9176 TNC change is associated with the severe neonatal-onset Leigh syndrome (Dionisi-Vici et al., 1998; Hung and Wang, 2007) .
Phenotypic variability (Table 2) in this family cannot be explained by the mutant load, and other factors (nuclear modifying genes or the mtDNA background) may be involved in the phenotypic expression of the disease. Moreover, three additional mitochondrial encoded genes have been identified in HSP (PGN, HSPD1, and OPA3), focusing on the importance of mitochondrial dysfunction (reviewed in Salinas et al., 2008) .
Other phenotypes
SPOAN syndrome (complicated spastic paraplegia associated with optic atrophy and neuropathy) linked to 11q13 (Macedo-Souza et al., 2005) , a complex phenotype in a Japanese family (Hattori et al., 2010) , and a complex HSP related to oligodendropathy (Woehrer et al., 2012) await molecular definition.
Functional modules
HSP is characterized by clinical and genetic heterogeneity, caused by a large number of loci/genes involved. Proteins implicated in the onset of the disease are part of specific molecular pathways or perform similar functions and the same protein can be implicated in several functions. Ten principal functional modules (Fig. 2) have been summarized, which are also presumed to create interactome networks (Novarino et al., 2014) .
Oxidative stress in HSP pathogenesis PGN mutations determine the lack of the paraplegin/AFG3L2 complex, responsible for a specific quality control of proteins that are localized in the inner mitochondrial membrane; moreover, this complex is also involved in a chaperone-like activity on the OXPHOS (oxidative phosphorylation pathway) protein complexes (Maltecca et al., 2009 ). The impairment in complex I activity has been observed in SPG7 subjects and an increased sensitivity to oxidative stress has been measured in their fibroblasts (reviewed in Rugarli and Langer, 2006) . Paraplegindeficient mice showed axonal degeneration with an abnormal mitochondrial morphology and impairment in axonal transport (Ferreirinha et al., 2004) , indicating a role for paraplegin in axon maintenance. A recent work has underlined the crucial role of both AFG3L2 and paraplegin in preventing neuronal death and, in particular, their ability to inhibit cerebellar degeneration (Martinelli et al., 2009) .
HSP60 functions only in combination with HSP10, forming a barrellike structure. Compared to controls, no particular mitochondrial dysfunction has been observed in SPG13-patients; however, it has been demonstrated that their cells show a decreased expression of two quality control mitochondrial proteases Lon and ClpP (Hansen et al., 2008) . Instead, an abnormal functioning of mitochondrial respiratory chain complex I and IV has been found in a patient carrying a mutation in REEP1 (Hewamadduma et al., 2009) .
MT-ATP6 encodes a subunit of ATP synthase (Complex V). It leads to complex V instability, impaired assembly, and function. Phenotypic similarity has been observed between patients carrying mitochondrial DNA (mtDNA) mutations and HSP patients. On the basis of these observations, a recent work evaluated the possible involvement of common mitochondrial polymorphisms/haplogroups on the risk of developing HSP (Sánchez-Ferrero et al., 2011) .
Dysfunction of axonal transport
Axonal transport is believed to be primarily impaired in several HSP forms. Well-characterized proteins will be focused on: spastin, kinesin HC5A, and kinesin 3.
Spastin has a complex subcellular localization based on its different isoforms (Lumb et al., 2012) . The full-length isoform is mainly localized on the early secretory pathway, at the ER and probably also at the very early ER-to-Golgi intermediate compartment. In contrast, the isoform that lacks the first 87 amino acids stretch exists in a cytosolic pool and can be recruited to endosomes and to the cytokinetic midbody during cell division. This isoform has also been described in the nucleus due to two nuclear localization signals. While the wildtype over-expressed form of spastin causes disassembly of microtubules, the mutated form localizes with them (Errico et al., 2002) . With reference to the disassembly of microtubules, the spastin seems to act in a hexameric form that binds polymerized tubulin and induces a conformational change responsible for breaking microtubules. A recent work has described a post-translational glutamylation of tubulin (the generation of long glutamate side chains) that is a necessary step for spastin-dependent microtubule disassembly (Lacroix et al., 2010) . The spastin MIT domain also mediates the interaction with the charged multi vesicular body proteins. These proteins form a complex named ESCRT-III, involved in viral budding, formation, and sorting of cargoes into the late endosomes, as well as in the resolution of the midbody membrane (Raiborg and Stenmark, 2009) . Spastin also interacts with protrudin. The lack of protrudin in cultured neurons inhibits neurite extension, whereas its over-expression promotes neurite extension (Shirane and Nakayama, 2006) . Moreover, a loss of spastin is suggested to reduce the rate of axonal branching in cultured primary neurons (Riano et al., 2009) . Post mortem analysis of SPG4 reported abnormalities in the distribution of mitochondria in spinal motor neurons, emphasizing the spastin involvement in organelles axonal movement (McDermott et al., 2003) .
In mammals, kinesin HC5A is necessary for anterograde axonal transport of neurofilament subunits and it plays a role in the transport of other anterograde cargoes, for example membrane vesicles (Reid et al., 2002) . Experimental data suggested that when KIF5A is mutated, cargo transport to the distal axon is slowed, or microtubules binding affinity is decreased. Consequently, the frequency of anterograde transport is lowered, and the arrival of the cargo to the synapse is largely delayed. Alternatively, axonal degeneration in patients with HSP subtypes may be caused by impaired slow axonal transport. Indeed, the lack of neurofilament supply to the synapsis is a plausible reason for neurodegeneration (Ebbing et al., 2008) .
Kinesin 3 is a highly processive and fast motor protein belonging to the homonymous family of microtubule-associated proteins involved in intracellular transport (Lo et al., 2011) . It is responsible for fast axonal transport of DCVs, implicated in carrying organelles in neurons responsible for transporting and secreting neuropeptides, but it remains associated with them during retrograde axonal transport too. This protein contains multiple protein-protein interaction domains that facilitate differential cargo binding. Additionally, Park et al. (2008) demonstrated that the complex containing dynactin-kinesin 2/kinesin 3 interacts with carboxypeptidase E, which plays an important role in the transport of pituitary hormones vesicles; yet, the exact mechanism of binding to DCVs is not known.
Abnormal lipid metabolism
Some proteins involved in HSP play a role in lipid metabolism at various levels.
CYP7B1 is one of two CYP7 family members, which is expressed in several tissues (liver, kidney, and brain) (Siam et al., 2012) . In the brain, this hydroxylase is implicated in steroid hormone metabolism, acting toward two neurosteroids, pregnenolone and dehydroepiandrosterone (DHEA), (Lorbek et al., 2012) . CYP7B1 is also important for the 7-hydroxylation of DHEA-related hydroxysteroids. Some data suggest that this group of neurosteroids act as neuroprotective factors and they can reduce ischemia-induced neurodegeneration. Consequently, neurodegeneration associated with CYP7B1 mutation may also be associated with a loss of neuroprotective function of DHEA-related neurosteroids .
PNPLA6 is a phospholipase/lysophospholipase and its activity may be regulated by cAMP. The protein participates in the regulation of phospholipid homeostasis necessary for maintaining cellular membrane integrity. In particular, it acts as a phospholipase B promoting phospatidylcholine conversion to glycerophosphocholine. Knockout experiments show that it is indispensable for survival of the embryo and maintenance of axons in adults; acetylation of gangliosides and glycoproteins may also play a significant role (Moser et al., 2004) .
Abnormal DNA repair
AP5Z1 is a putative helicase with both nuclear and cytoplasmic localization (Słabicki et al., 2010) . It interacts with four proteins, probably forming a complex required for an efficient homologous recombination DNA double-strand break repair. Two of the interaction partners, spatacsin and spastizin, are proteins associated with spastic paraparesis. Indeed, spatacsin is phosphorylated upon DNA damage by protein kinases ATM (ataxia telangiectasia mutated) or ATR (ATM and Rad3-related).
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T. Lo Giudice et al. / Experimental Neurology 261 (2014) 518-539 Dysregulation of myelination MPLP is involved in myelin sheath stabilization and axon-myelin interactions, whereas DM20, its splicing variant, is involved in oligodendrocyte maturation (Inoue, 2005) . The large part of misfolded MPLP/ DM20 is retained in the ER. The presence of misfolded proteins induces a cascade of protein interactions and dissociations. The chaperone binding immunoglobulin protein (BiP) associates with three stress sensors (PERK, IRE1, and ATF6), maintaining these proteins in an inactive state. Upon stress induction, BiP dissociates, translocates to the ER lumen to assist in protein folding, and the sensor proteins adopt an active status. The activated proteins induce a series of interacting pathways constituting the UPR that leads to apoptosis of oligodendrocytes (Swanton et al., 2003) .
FA2H is an NADPH-dependent monooxygenase highly expressed in oligodendrocytes and it is involved in the biosynthesis of mammalian sphingolipids . FA2H synthesizes 2-hydroxy fatty acids: these are incorporated into ceramide, a precursor of galactosylceramide and one of the major constituents of the myelin sheath. 2-hydroxylation stabilizes lateral interactions between sphingolipids and membrane-membrane interactions (Zöller et al., 2008 ). An alteration of this mechanism suggests that transport and/or degradation of myelin components might be affected.
GJC2 mutations disrupt junction channels between astrocytes and oligodendrocytes causing cell-cell communication impairment in maintenance of CNS myelin (Orthmann-Murphy et al., 2009) .
Autophagy
It was hypothesized that the truncated KIAA0329 protein would lead to dysregulation of the intracellular autophagy pathway, with reduced delivery of two targeted autophagocytic proteins (SQSTM1 and MAP1LC3B) to lysosomes (Oz-Levi et al., 2012) .
Spastizin has been suggested to be associated with the AP5 complex in endolysosomal function (Khundadze et al., 2013) . In lymphoblast and fibroblast cells derived from spastizin mutated patients, it has been demonstrated an impairment of autophagosome maturation with accumulation of immature autophagosomes (Vantaggiato et al., 2013) .
Axon development
Neural cell adhesion molecule (NCAM) plays an important role in the development of the nervous system, promoting neuron-neuron adhesion and axon outgrowth. These crucial cellular events are permitted by NCAM interactions with other cell adhesion molecules (CAMs). NCAM molecular partners determine its function; in fact, NCAMintegrin binding modulates adhesion to extracellular matrix proteins, whereas the interaction between NCAM and TAG1 (transient axonal glycoprotein-1) is necessary for NCAM-NCAM mediated neurite outgrowth (Kenwrick et al., 2000) .
MCT8 is expressed in neurons and cerebral microvessels in all species; its role in the transport of T4 from the blood into the cerebrospinal fluid and in efflux of thyroid hormones or their inactive metabolites from the cerebrospinal fluid to blood was also suggested as a cause of axon impairment (Roberts et al., 2008) .
Endosome membrane trafficking and vesicle formation
Adaptor protein complexes (AP1-4) are ubiquitously expressed and mediate different types of vesicle formation and their molecular cargo selection from the trans-Golgi compartment to the endosomal-lysosomal system. AP4-mediated trafficking can be involved in brain development and functioning (Abou Jamra et al., 2011) . It is also involved in the transport of amyloid precursor protein (APP) from the trans-Golgi network to early endosomes (Burgos et al., 2010) .
VPS37A is a component and an upstream regulator of the ESCRT-I; its depletion delays EGF receptor degradation (Bache et al., 2004) .
Strumpellin is a component of the Wiskott-Aldrich syndrome protein and scar homolog (WASH) complex, an actin-regulating complex present at the surface of endosomes, which regulates the correct subcellular distribution of the β-2-adrenergic receptor; corticospinal neurons are especially vulnerable to reductions in functional WASH (Freeman et al., 2013) .
Abnormal cellular signaling in protein morphogenesis
Atlastin-1, NIPA1, spastin, and spartin have been shown to inhibit bone morphogenetic protein (BMP) signaling (Tsang et al., 2009 ). This suggests that the up-regulation of BMP pathway by loss-of-function mutation in these genes could be a common pathogenic mechanism in the disease.
Atlastin-1 regulates the axons architecture by down-regulating BMP signaling during zebrafish development (Fassier et al., 2010) . As a matter of fact, the early depletion of this protein leads to severe defects in axons, with consequent marked decrease of larval mobility. Functional studies have demonstrated that atlastin-1 partially co-localizes with BMP receptor type I in late endosomes, probably regulating the receptor trafficking.
NIPA1 protein is mainly expressed in early endosomes and cell surface. It contains nine transmembrane domains and it is suggested to partake in cellular magnesium metabolism. Recent evidences show that NIPA1 and atlastin-1 are direct binding partners, since cellular distribution of atlastin-1/NIPA1 complexes is dramatically altered by HSP-causing mutations (Botzolakis et al., 2011) . In addition, NIPA1 inhibits BMP signaling by promoting endocytosis and lysosomal degradation of the type II BMP receptor (BMPRII). Mutant NIPA1 is retained in the ER and alters BMPRII trafficking (Tsang et al., 2009) .
Spartin is involved in epidermal growth factor receptor (EGFR) intracellular trafficking and an impaired endocytosis of EGFR by mutant spartin would cause the onset of Troyer syndrome. Low levels of EGF cause the internalization of EGFR via clathrin-mediated endocytosis. Spartin knockdown decreases the rate of EGFR degradation and affects EGFR internalization, recycling, or both. Conversely, spartin over-expression results in a prominent decrease in EGFR degradation. The molecular mechanisms leading to the redistribution of spartin are unknown. It is believed that EGFR activation might induce the phosphorylation of spartin, leading to its translocation to the plasma membrane (Bakowska et al., 2007) .
SPFH2 is a protein with the ability to assemble into oligomeric structures and localize in cholesterol-rich membranes (Pearce et al., 2009) . As previously mentioned, it is involved in the ER degradation pathway that target both aberrant and normal proteins to maintain homeostasis. SPFH2 depletion causes impaired degradation of inositol-1,4,5-trisphosphate (IP3); it leads to a persistent activation of IP3 signaling and channel opening, determining neuronal hyperactivity (Alazami et al., 2011) .
Abnormal membrane traffic and organelle shaping
Spastin, atlastin, REEP1, and reticulon 2 take part in ER membrane modeling and shaping. These proteins share similar hairpin loops that control ER membrane shaping.
Reticulon 2 overexpression determines the formation of tubular ER membrane structures. It acts together with DP1/Yop1 proteins in stabilizing the ER membrane curvature at the sheets edges. Moreover, the different quantitative expression of these proteins is responsible for ER morphology (Shibata et al., 2010) . Atlastin controls ER tubules fusion in order to create the ER network; it is noteworthy that morphology of the tubular ER depends on microtubules dynamics that, in turn, depend on spastin function. Mutual interactions between spastin, REEP1, and atlastin-1 make these peptides responsible for the ER network formation and membrane bending. A truncated REEP1 protein causes the disruption of ER morphology by interfering with REEP1-microtubules binding; this hypothesis expects that these three proteins cooperate in protein trafficking along microtubules and the loss of function of these peptides leads to a damage of the long axons of the corticospinal tract (Park et al., 2010) .
Diagnosis
HSP can be suspected when the following differential diagnoses have been excluded: leukodystrophies, subacute combined degeneration of spinal cord (vitamin B12 deficiency), multiple sclerosis (absence of oligoclonal bands in CSF in HSP), acyl-CoA dehydrogenase deficiency (VLCAD), copper deficiency, Segawa disease (DYT5), HTLV-1-associated myelopathy, amyotrophic lateral sclerosis, primary lateral sclerosis, arginase deficiency, Friedreich's ataxia, mitochondrial disorders, early onset Alzheimer disease with spastic paraparesis caused by presenilin 1 mutations, structural abnormalities of brain and spinal cord, and lumbar vertebral stenosis. Also, spinocerebellar ataxias (SCA) can mimic HSP: SCA3 (ATXN3) and autosomal recessive SCA (APTX, SETX, POLG, TDP1, SACS, SYNE1, C10orf2, SCAR3, and SCAR7) should be excluded in selected patients.
Diagnostic steps include individual and family history to detect the type of transmission. A careful neurological examination, neurophysiological testing, and instrumental investigations (MEPs, SEPs, VEPs, AEPs, electroneurography/EMG, MRI, EEG, and cystometry) are needed in diagnosis; pure and complex forms shall be identified before starting genetic testing. Prolonged central conduction time in MEPs and SEPs indicates the central long tract impairment. Neuroimaging analyses would provide early clues to the diagnosis of HSP. Thinning or atrophy of corpus callosum as well as cervical and thoracic spinal cord has been observed on conventional MRI studies (Lan et al., 2014; Orlacchio et al., 2011) . Diffusion tensor imaging (DTI) successfully showed HSPrelated microstructural alterations in white matter. DTI could reveal abnormality of white matter integrity, especially at the corticospinal tract, in the early stage of SPG4 (Duning et al., 2010) . Specific statistical analyses clearly showed alterations in multiple DTI indices, such as decreased fractional anisotropy and increased radial diffusivity, indicating loss of myelin integrity in HSP patients, including SPG3, SPG4, SPG5, SPG7, and SPG10. Intriguingly, a decreased fractional anisotropy was observed in the frontal circuitry, suggesting subtle disruption of the frontal connections (Aghakhanyan et al., 2014) . Neuropathological investigations may detect axonal degeneration of the corticospinal tract, loss of anterior horn cells, or demyelination consistent with axonal degeneration (Deluca et al., 2004) .
Screening for SPG mutations is usually carried out by direct Sanger sequencing coupled with multiplex ligation-dependent probe amplification (Battini et al., 2011) . The improvement of nucleotide sequencing has recently demonstrated the possibility of accelerating and improving cost-effectiveness of genetic diagnosis using an array-based amplification strategy after generation of amplicon libraries of all currently known HSP genes followed by a pooled next-generation sequencing (NGS) (Chase, 2014; Novarino et al., 2014; Schlipf et al., 2011) . Besides, modern methodologies of re-sequencing have been reported as well as a gene chip screening (Luo et al., 2013) .
Being molecular genetic testing available on a routine basis only for a few HSP forms (SPG3A, SPG4, SPG6, SPG7, SPG10, SPG11, SPG17, and SPG31) we propose two algorithms (Fig. 3) for genetic testing.
Treatment
Treatment is exclusively symptomatic. Spasticity benefits from daily physical therapy (swimming, in particular), baclofen or tizanidine. If ineffective, intramuscular injections of botulinum toxins A or B can be considered, especially in cases associated with dystonia (Geva-Dayan et al., 2010) . Long-term intrathecal baclofen therapy can be administered via a surgically implanted programmable pump (Motta and Antonello, 2014) . A recent study focused on gait and hydrotherapy treatment in patients with late onset HSP demonstrating increased walking speed mediated by compensatory strategies (Zhang et al., 2014) . Deep brain stimulation has also been used in dystonia (Gilbert et al., 2009) . Hypertonic bladder benefits from anticholinergic drugs and neuropathic pain from gabapentin or pregabalin. Parkinsonism, dementia, and epilepsy are treated according to the respective guidelines. Hearing devices in SPG29 and shunt implantations in SPG1 developing hydrocephalus are often used. Regular clinical revaluations of patients once or twice yearly are recommended to assess progression and complications.
Potential therapies
The availability of HSP animal models, including mouse, rat, zebrafish, cattle, Drosophila, and C. elegans (reviewed in Fink, 2013) , not only allows the exploration of disease mechanisms, but also of potential treatments. Future prospects will allow a rational approach to intracellular transport defects (Soderblom and Blackstone, 2006) , in particular microtubules dysfunction in SPG4 Drosophila models in which mutated spastin leads to an excessive stabilization of microtubules in the neuromuscular junction synapse: agents destabilizing microtubules, like nocodazole (Trotta et al., 2004) and vinblastine (Orlacchio et al., 2004b; Orso et al., 2005) , seem to attenuate HSP-like phenotypes in vivo.
If 27-hydroxycholesterol was a major factor in the degeneration of corticospinal tracts in SPG5-patients, an effective therapeutic approach should aim at reducing its levels. A possible therapeutic strategy might be a statin treatment. It has been observed that the levels of 27-hydroxycholesterol and cholesterol decrease in parallel during statin therapy, limiting the synthesis (CYP27A1 activity) by a substrate availability (Schüle et al., 2010) . Recent findings of moderate reductions of serum 27-hydroxycholesterol upon simvastatin administration in a SPG5-patient led to interesting possibilities on SPG5 treatment (Mignarri et al., 2014) .
A gene transfer study showed that adenoassociated virus-mediated (AAV-mediated) intramuscular delivery of paraplegin halts the progression of neuropathological changes and rescues mitochondrial morphology in the peripheral nerves of paraplegin-deficient mice, suggesting that viral vectors can be the key to treat genetic diseases (Pirozzi et al., 2006) .
Food for thought
Pure and late onset HSP forms are generally inherited following an AD pattern, whereas ARHSPs often associate with early, more severe onset, and complex phenotypes.
The evidence that degeneration may also regard shorter axons, for example in the cerebellum, neocortex, corpus callosum, and optic nerve, suggests that length-dependent distal axon degeneration is not the only pathogenetic mechanism involved (White et al., 2000) .
Different clinical features reflect genetic heterogeneity in HSP. Many genes are implicated in selective clinical manifestations, while the same gene is mutated in various diseases (see among others, the ample allelisms of BSCL2 and FA2H). It is well known that mutated genes alter specific intracellular (or cell-to-cell) mechanisms bringing different clinical features. The identification of causative genes in HSP revealed that the common axonal degeneration has different pathogenetic mechanisms. This overlaps with other neurodegenerative diseases, in particular distal spinal muscolar atrophy (SMA), juvenile amyotrophic lateral sclerosis (JALS), and CMT. Indeed, BICD2 mutations, encoding a key adaptor protein involved in trafficking of cellular cargos, are reported in patients showing both HSP and autosomal dominant congenital SMA (DCSMA) (Oates et al., 2013) . Lower motor neuron degeneration in HSP overlaps with JALS, as evidenced by the identification of KIAA1840 mutations in 40% of JALS-patients (Orlacchio et al., 2010) and by the dysfunction of endosomal trafficking in ALS2 mutated JALS-patients (Hadano et al., 2007) . This concept also concerns CMT neuropathies (primarily CMT2), which show many similarities with HSP (reviewed in Timmerman et al., 2013) in terms of clinical presentation, molecular genetics, and cellular pathology. In particular, a KIF5A mutation, p.G235E, has been found in a patient affected by axonal CMT and member of an HSP family; this suggests that SPG10 and CMT may be the extreme phenotypes resulting from mutations in the same gene . Finally, by using the random walk distance algorithm in HSP genes network, Novarino et al. (2014) linked HSP to amyotrophic lateral sclerosis, Alzheimer's disease, and Parkinson's disease.
Therefore, the recognition of common molecular themes in motor neuron diseases could clarify the bases of neurodegeneration and justify therapeutic strategies, which are not limited to individual subtypes, but rather based on pathway/module impairment. 
